Clinical Trials Logo

Hodgkin Disease clinical trials

View clinical trials related to Hodgkin Disease.

Filter by:

NCT ID: NCT03436862 Completed - Hodgkin Lymphoma Clinical Trials

Nivolumab Maintenance Therapy After Autologous Stem Cell Transplant in Hodgkin Lymphoma Pts at Relapse/Progression Risk

Start date: May 23, 2018
Phase: Phase 2
Study type: Interventional

This is a Phase II single-arm open-label study of nivolumab as maintenance therapy after autologous stem cell transplantation in patients with Hodgkin lymphoma at risk of relapse or progression.

NCT ID: NCT03343665 Completed - Hodgkin Lymphoma Clinical Trials

Treatment With Nivolumab at the Fixed Dose 40 mg (Nivo40) in Patients With Relapsed/Refractory Hodgkins Lymphoma

Nivo40
Start date: August 1, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

A phase I/II trial to evaluate the safety and efficacy of nivolumab at the fixed dose 40 mg in patients with relapsed or refractory Hodgkins lymphoma.

NCT ID: NCT03343652 Completed - Hodgkin's Lymphoma Clinical Trials

A Study of Safety and Efficacy of Nivolumab and Bendamustine (NB) in Patients With Relapsed/Refractory Hodgkin's Lymphoma

NB001
Start date: May 27, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

A clinical study of safety and efficacy of treatment with Nivolumab and Bendamustine (NB) in patients with relapsed/refractory Hodgkin's lymphoma.

NCT ID: NCT03327571 Completed - Clinical trials for Classical Hodgkin Lymphoma

B-CD30 + Hodgkin Lymphoma International Multi-center Retrospective Study of Treatment Practices and Outcomes

B-HOLISTIC
Start date: November 21, 2017
Phase:
Study type: Observational

The purpose of this study is to describe progression-free survival (PFS) in participants with relapsed or refractory classical Hodgkin lymphoma (RRHL), defined as the time from initiation of first treatment for RRHL to first documentation of relapse or disease progression, or death.

NCT ID: NCT03323541 Completed - Multiple Myeloma Clinical Trials

Use of Zarzio® in Post-autologous Stem Cell Transplantation Procedure

ZAPA
Start date: November 3, 2016
Phase:
Study type: Observational

There are limited data concerning the use of biosimilars of filgrastim in autologous stem cell transplantation (ASCT). This study aimed to evaluate G-CSF efficiency and safety (based on haemograms, transfusion needs and complications) of two biosimilars (Zarzio and Ratiograstim®) compared to those of Neupogen® for our patients who underwent ASCT.

NCT ID: NCT03302728 Completed - Hodgkin Lymphoma Clinical Trials

Brentuximab Vedotin and Lenalidomide in Patients With Relapsed/ Refractory T-cell Lymphoma or Hodgkin Lymphoma

EpiBrentlen
Start date: August 30, 2018
Phase: Phase 1
Study type: Interventional

This study is investigating the combination of Brentuximab vedotin and lenalidomide in the treatment of relapsed/refractory peripheral T cell lymphoma or cutaneous T cell lymphoma or Hodgkin lymphoma. It is hypothesised that lenalidomide may augment the actions of Brentuximab vedotin in these patient groups. The primary objective of the study is to determine the maximum tolerated dose of the combination treatment, which can be used in subsequent studies. The study will also investigate disease response and survival. Participants will receive Brentuximab vedotin (once every 21 days i.e. 1 cycle) and lenalidomide (daily from day 1 -14 of each cycle) for a maximum of 48 weeks and will be followed for a subsequent 6 months after the end of treatment.

NCT ID: NCT03209973 Completed - Clinical trials for Classical Hodgkin Lymphoma

A Study of Tislelizumab as Monotherapy in Relapsed or Refractory Classical Hodgkin Lymphoma

Start date: April 21, 2017
Phase: Phase 2
Study type: Interventional

The primary objective of this study was to evaluate the efficacy of tislelizumab assessed by Independent Review Committee (IRC) in participants with relapsed or refractory classical Hodgkin lymphoma (cHL), as measured by Overall Response Rate (ORR) per the Lugano Classification

NCT ID: NCT03155425 Completed - Clinical trials for Hodgkin Lymphoma, Adult

PD-1 Antibody SHR-1210 in Patients With Relapsed or Refractory Classic Hodgkin's Lymphoma

Start date: June 9, 2017
Phase: Phase 2
Study type: Interventional

This is an open-label, multicenter, non-randomized, phase 2 trial to evaluate efficacy and safety of SHR-1210 in patients with relapsed or refractory classic Hodgkin's lymphoma. The primary objective is to assess ORR of SHR-1210 in patients with relapsed or refractory classic Hodgkin's lymphoma.

NCT ID: NCT03114683 Completed - Clinical trials for Relapsed/Refractory Classical Hodgkin's Lymphoma

Efficacy and Safety Evaluation of IBI308 in Treatment of Patients With Relapsed/Refractory Classical Hodgkin's Lymphoma

ORIENT-1
Start date: March 30, 2017
Phase: Phase 2
Study type: Interventional

The study is to evaluate ORR, CR, PR DCR DOR PFS and safety of IBI308 in treatment of patients with Relapsed/Refractory Hodgkin's Lymphoma.

NCT ID: NCT03107663 Completed - Hodgkin Lymphoma Clinical Trials

⁸⁹Zr-Df-IAB22M2C PET/CT in Patients With Selected Solid Malignancies or Hodgkin's Lymphoma

Start date: June 19, 2017
Phase: Phase 1
Study type: Interventional

To determine the safety and feasibility of 89Zr-Df-IAB22M2C as an immunoPET tracer; determine the best time window and protein dose for imaging; determine the pharmacokinetic (PK) and biodistribution of the probe; and to determine imaging parameters for optimal lymphoid and tumor visualization.